Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: tumour necrosis factor-alpha inhibitor antibodies - Numab/Tillotts

Drug Profile

Research programme: tumour necrosis factor-alpha inhibitor antibodies - Numab/Tillotts

Alternative Names: Anti-TNF therapy - Numab/Tillotts; Antibody-based inflammatory bowel disease therapeutics - Numab/Tillotts; ND-009; NM 09 programme; NM-09; TNF-alpha blockers - Numab/Tillotts; TNF-α inhibitor antibodies- Numab/Tillotts; Tumour necrosis factor-alpha blockers - Numab/Tillotts

Latest Information Update: 09 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Numab
  • Developer Numab; Tillotts Pharma
  • Class Anti-inflammatories; Antibodies; Immunoglobulin Fv fragments
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 26 Aug 2020 ND 009 is available for licensing as of 26 Aug 2020. https://www.tillotts.com/partnering/partner-with-tillotts/ (Numab pipeline, August 2020)
  • 28 Jul 2019 No recent reports of development identified for research development in Inflammatory-bowel-diseases in Switzerland (Parenteral)
  • 09 Jun 2015 TNF-α inhibitor antibodies licensed to Tillotts Pharma worldwide for the treatment of inflammatory bowel disease
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top